Position paper on imatinib mesylate in chronic myeloid leukaemia

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.

Molecular cancer therapeutics·2019

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.

The Lancet. Haematology·2019

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.

The Lancet. Haematology·2017

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

The New England journal of medicine·2017

Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences.

British journal of haematology·2012

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).

Blood·2010

BCMA versus GPRC5D bispecific antibodies in relapsed/refractory multiple myeloma: A systematic review and meta-analysis guiding treatment selection.

British journal of haematology·2026

Development and validation of a machine learning model based on routine laboratory tests for predicting FLT3-ITD mutations in acute myeloid leukaemia.

British journal of haematology·2026

Haploidentical haematopoietic stem cell transplantation for thalassaemia major: A phase IV, open-label, single-centre trial.

British journal of haematology·2026

Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma.

British journal of haematology·2026

Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.

British journal of haematology·2026

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma.

British journal of haematology·2026

Mixed exocrine-neuroendocrine intraductal papillary mucinous neoplasms of the pancreas: a case series.

Oxford medical case reports·2026

Tuft cells contribute to the pathogenesis of human primary and experimental murine Sjögren's disease.

Journal of dental sciences·2026

Inflammatory Myofibroblastic Tumor of the Central Airways: Case Report and Review of Diagnostic and Therapeutic Strategies.

Case reports in pulmonology·2026

Prematurity is associated with altered central thyroid hormone sensitivity.

Frontiers in endocrinology·2026

From peripheral blood to tumor microenvironment: spatial dimension deficiency and paradigm reconstruction in immunotherapy biomarker research.

Frontiers in immunology·2026

CD161 and LLT1 expression in immune cell populations of Hodgkin lymphoma tumor microenvironment.

Frontiers in medicine·2026

Related Experiment Videos

Position paper on imatinib mesylate in chronic myeloid leukaemia

Related Concept Videos

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors.

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences.

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).

BCMA versus GPRC5D bispecific antibodies in relapsed/refractory multiple myeloma: A systematic review and meta-analysis guiding treatment selection.

Development and validation of a machine learning model based on routine laboratory tests for predicting FLT3-ITD mutations in acute myeloid leukaemia.

Haploidentical haematopoietic stem cell transplantation for thalassaemia major: A phase IV, open-label, single-centre trial.

Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma.

Survival after first relapse in marginal zone lymphomas: Prospective data from the international observational NF10 study.

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma.

Mixed exocrine-neuroendocrine intraductal papillary mucinous neoplasms of the pancreas: a case series.

Tuft cells contribute to the pathogenesis of human primary and experimental murine Sjögren's disease.

Inflammatory Myofibroblastic Tumor of the Central Airways: Case Report and Review of Diagnostic and Therapeutic Strategies.

Prematurity is associated with altered central thyroid hormone sensitivity.

From peripheral blood to tumor microenvironment: spatial dimension deficiency and paradigm reconstruction in immunotherapy biomarker research.

CD161 and LLT1 expression in immune cell populations of Hodgkin lymphoma tumor microenvironment.

Related Experiment Videos

Position paper on imatinib mesylate in chronic myeloid leukaemia

Related Concept Videos

Related Articles